---
title: "(NU/1433-36) IndigoDX Ltd: Commercialisation of university research through provision of management skills to assist in successful spin-out company creation"
ocid: "ocds-h6vhtk-0371b3"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0371b3"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-0371b3.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-0371b3.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "NEWCASTLE UNIVERSITY"
published: "2022-09-30"
---

# (NU/1433-36) IndigoDX Ltd: Commercialisation of university research through provision of management skills to assist in successful spin-out company creation

Buyer: NEWCASTLE UNIVERSITY  
Current stage: Award  
OCID: ocds-h6vhtk-0371b3

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0371b3)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-0371b3.json)

## Summary

The Newcastle University has awarded a contract for the commercialisation of university research to DU Biosciences. The project involves creating a diagnostic tool for urinary symptoms caused by an overactive bladder to improve treatment outcomes. The procurement process was completed under a selective procurement method, with a cancelled status. The value of the contract signed on 6th September 2022 is £30,000.

This tender presents business growth opportunities for high-tech start-ups with experience in securing seed investment and establishing manufacturing facilities. Companies in the business and management consultancy sector may find this opportunity suitable. The University is seeking a driven executive to lead the project, build a compelling investment proposition, and establish collaborative research projects to advance the technology.

## Notice

1 in 5 adults in the UK suffer from urinary symptoms caused by an overactive bladder (OAB). Symptoms include urgency (a sudden compelling desire to pass urine, which cannot be deferred), increased frequency of voiding (both day and night) and urge incontinence (involuntary leakage accompanied by / immediately preceded by urgency). The Team wishes to establish a spinout company to produce a Dipstick-style test. Our discovery is currently being developed into a simple-to-use diagnostic tool used for (1) regular screening for OAB in adults, at a GP surgery, pharmacy or nursing home, and (2) to assess the effectiveness of treatments (companion diagnostic) and modifying dosing/treatments accordingly. Accurate and early diagnosis will improve treatment outcomes, eliminating the need for patients to have invasive and high-risk surgery-led second-line treatments necessary for advanced-stage disease. Currently there is no competition for a non-invasive biomarker-based test, and new product development activity appears to be very limited, suggesting an opportunity for 'first mover advantage' and to establish a standard. We require a driven executive to take this technology forward and build a compelling proposition for investment. The Executive will need to create a robust business model that is acceptable to the founders, develop and deliver pitch materials for investors and establish collaborative research projects. The executive appointed should have an appropriate background, ideally with experience of high tech starts ups, securing seed investment and establishing manufacturing facilities.

### Lot Information

Lot 1

1 in 5 adults in the UK suffer from urinary symptoms caused by an overactive bladder (OAB). Symptoms include urgency (a sudden compelling desire to pass urine, which cannot be deferred), increased frequency of voiding (both day and night) and urge incontinence (involuntary leakage accompanied by / immediately preceded by urgency). The Team wishes to establish a spinout company to produce a Dipstick-style test. Our discovery is currently being developed into a simple-to-use diagnostic tool used for (1) regular screening for OAB in adults, at a GP surgery, pharmacy or nursing home, and (2) to assess the effectiveness of treatments (companion diagnostic) and modifying dosing/treatments accordingly. Accurate and early diagnosis will improve treatment outcomes, eliminating the need for patients to have invasive and high-risk surgery-led second-line treatments necessary for advanced-stage disease. Currently there is no competition for a non-invasive biomarker-based test, and new product development activity appears to be very limited, suggesting an opportunity for 'first mover advantage' and to establish a standard. We require a driven executive to take this technology forward and build a compelling proposition for investment. The Executive will need to create a robust business model that is acceptable to the founders, develop and deliver pitch materials for investors and establish collaborative research projects. The executive appointed should have an appropriate background, ideally with experience of high tech starts ups, securing seed investment and establishing manufacturing facilities.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/027450-2022 |
| Notice type | Award Notice |
| Procurement type | Dynamic |
| Procurement category | Services |
| Procurement method | Selective |
| Procurement method details | Restricted procedure |
| Tender suitability | Not specified |
| Awardee scale | SME |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 30 Sep 2022 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 5 Sep 2022 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £30,000 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NEWCASTLE UNIVERSITY |
| Additional buyers | DURHAM UNIVERSITY; EUROPEAN UNION; NORTHUMBRIA UNIVERSITY NEWCASTLE NEWCASTLE; TEESSIDE UNIVERSITY; UNIVERSITY OF BATH ON BEHALF OF THE SETSQUARED; UNIVERSITY OF SUNDERLAND |
| Locality | NEWCASTLE |
| Post town | Newcastle upon Tyne |
| Postcode | NE1 7RU |
| Country | England |
| ITL 1 | TLC North East (England) |
| ITL 2 | TLC4 Northumberland, Durham and Tyne & Wear |
| ITL 3 | TLC43 Tyneside |
| Local authority | Newcastle upon Tyne |
| Electoral ward | Monument |
| Westminster constituency | Newcastle upon Tyne Central and West |
| Delivery location | TLC North East (England) |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 1 |
| Supplier names | DU BIOSCIENCES |

## CPV Codes

### Divisions

- 79 - Business services: law, marketing, consulting, recruitment, printing and security

### Codes

- 79400000 - Business and management consultancy and related services

## Release History

- 30 Sep 2022 at 10:32 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/027450-2022

## Notice URLs

- https://Sunderland.ac.uk
- https://northumbria.ac.uk
- https://ted.europa.eu/udl?uri=TED:NOTICE:528050-2022:TEXT:EN:HTML
- https://www.bath.ac.uk/
- https://www.durham.ac.uk
- https://www.ncl.ac.uk
- https://www.tees.ac.uk/

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0371b3. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-0371b3.json.